-
1 Comment
Betta Pharmaceuticals Co., Ltd is currently in a long term downtrend where the price is trading 10.1% below its 200 day moving average.
From a valuation standpoint, the stock is 133.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 22.5.
Betta Pharmaceuticals Co., Ltd's total revenue rose by 16.8% to $363M since the same quarter in the previous year.
Its net income has increased by 186.7% to $93M since the same quarter in the previous year.
Finally, its free cash flow fell by 68.0% to $8M since the same quarter in the previous year.
Based on the above factors, Betta Pharmaceuticals Co., Ltd gets an overall score of 2/5.
| ISIN | CNE100002DD9 |
|---|---|
| Exchange | SHE |
| CurrencyCode | CNY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Target Price | 63.79 |
|---|---|
| Market Cap | 21B |
| Dividend Yield | 0.4% |
| Beta | 0.56 |
| PE Ratio | 68.28 |
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of NSCLC; and Bevacizumab, an antibody drug against human vascular endothelial growth factor that is used to treat NSCLC, colorectal cancer, and other solid tumor indications. It also develops BPI-D0316, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeting T790M mutation; Vorolanib, a multi-target kinase inhibitor for various cancer treatment; EYP-1901, an investigational long-acting treatment for wet AMD, non-proliferative diabetic retinopathy, diabetic macular edema, and pmCNV; and MCLA-129, a bispecific antibody targeting both EGFR and c-Met. In addition, the company develops BPI-371153 for the treatment of patients with locally advanced or metastatic solid tumor or relapsed/refractory lymphoma; CFT8919, an in vitro and in vivo model of EGFR L858R-driven NSCLC; and Balstilimab, a human monoclonal antibody targeting programmed cell death protein 1 and an immune checkpoint inhibitor. Further, it develops a recombinant human serum albumin injection under the OsrHSA name; and products for the treatment of solid tumor under the BPI-452080, MRX2843, BPI-460372, BPI-221351, BPI-520105, BPI-572270, and BPI-585725 names. The company was founded in 2003 and is based in Hangzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300558.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
